Vericel
Update in progressVCEL (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Vericel is a commercial-stage biopharmaceutical company focused on cell therapies and specialty biologics for sports medicine and burn care in North America. It markets MACI, autologous cultured chondrocytes on a porcine collagen membrane for knee cartilage defects; Epicel, a permanent skin replacement for deep burns; and NexoBrid, an enzymatic eschar-removal therapy for deep burns. Formerly Aastrom Biosciences, renamed Vericel in 2014. Incorporated 1989; based in Cambridge, MA.
Company score
- Sentiment
- 0.04
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.02
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!